Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial “GIVE ME FIVE”-Reference-Cited by-同舟云学术

Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial “GIVE ME FIVE”

Published:2024-03-16 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Marvaso Giulia,Corrao Giulia,Repetti Ilaria,Lorubbio Chiara,Bellerba Federica,Zaffaroni Mattia^ORCID,Vincini Maria Giulia,Zerini Dario,Alessi Sarah,Luzzago Stefano,Mistretta Francesco Alessandro,Fodor Cristiana,Cambria Raffaella,Cattani Federica,Ceci Francesco,Musi Gennaro,De Cobelli Ottavio,Zilli Thomas,Gandini Sara,Orecchia Roberto,Petralia Giuseppe,Jereczek-Fossa Barbara Alicja

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-04876-8.pdf

Reference39 articles.

1. Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060

2. Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249

3. Lane JA et al (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15:1109–1118

4. Schaeffer E, An Y, Barocas, D, et al (2022) NCCN Guidelines Version 1.2023 Prostate Cancer. 2022. https://www.nccn.org/home/. Accessed 16 Oct 2023

5. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 14 (09–22) Gy. Int J Radiat Oncol Biol Phys 82:e17-24

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Curative Stereotactic Body Radiation Therapy for Prostate Cancer, There Is a High Possibility That 45 Gy in Five Fractions Will Not Be Tolerated without a Hydrogel Spacer;Cancers;2024-04-11